GlaxoSmithKline (GSK) agrees to buy dermatology firm Stiefel Laboratories for up to $3.6B. The...


GlaxoSmithKline (GSK) agrees to buy dermatology firm Stiefel Laboratories for up to $3.6B. The purchase fits squarely with CEO Andrew Witty's strategy to expand in consumer products and diversify away from pure pharmaceuticals.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs